Hospital

Dostarlimab in the neoadjuvant setting yielded a 100% clinical complete response in patients with rectal cancer.

A phase 2 trial showed that using ctDNA to guide adjuvant pembrolizumab therapy after surgery effectively cleared minimal residual disease and reduced recurrence in patients with resected mismatch repair-deficient (dMMR) solid tumors.

The study found that 4 weeks was the ideal time point to test for cTDNA.

Ochsner Children’s Hospital, in partnership with ISMP, has launched a fellowship to advance pediatric medication safety through hands-on training in key competencies, national safety strategies, interdisciplinary collaboration, and innovative tools such as AI and data dashboards.

AI may help to accurately classify pediatric sarcoma subtypes using digitized pathology images, potentially improving diagnosis and treatment accessibility across diverse health care settings.

Zoldonrasib, a novel oral KRAS G12D-selective inhibitor, demonstrated promising safety and early antitumor activity in patients with previously treated non–small cell lung cancer (NSCLC), offering a potential new targeted therapy for this underserved population.

NCCN updates colon cancer guidelines, emphasizing testing for DPYD gene variants before initiating fluoropyrimidine-based chemotherapy.

Explore the intriguing connections between bulldogs and human medical conditions, revealing insights into congenital disorders and their treatments.

Pyrotinib is a tyrosine kinase inhibitor that is independently developed in China.

The treatment received indications as a monotherapy and in combination regimen with carboplatin or cisplatin and gemcitabine.

A study reveals IVIG treatment shows no significant benefits over tocilizumab for severe COVID-19, highlighting higher adverse events and costs.

The combination yielded superior progression-free (PFS) survival compared with standard of care.

The investigators’ hypothesis is supported by phase 2 trial data in which hydronidone resulted in significant reversal of liver fibrosis in patients with chronic hepatitis B (CHB).

This component of scar tissue may have a role in kidney fibrosis for slowing disease progression and improving outcomes for patients with chronic kidney disease (CKD).

Patients in both arms achieved statistically significant rates of compliance up to 97%.

PAK5 is a protein that drives resistance to trastuzumab emtansine in patients with HER2+ breast cancer.

The Version 3.2025 update adds tislelizumab-based regimens as preferred first-line treatments and introduces new dosing schedules for PD-L1–positive esophageal squamous cell carcinoma.

The smartphone application-led delabeling also did not delay surgeries or procedures in the evaluated clinics.

Clinicians should not just focus on one single nucleotide polymorphism (SNP), but rather consider all SNPs because each factor causes unique adverse effects

Thrombosis occurs in approximately 20% of myeloproliferative neoplasms.

Experts attribute the increase of pertussis cases to declining DTaP vaccination rates.

Invasive pneumococcal disease trends have fluctuated greatly over the past 2 decades, with older adults remaining at the center of disease burden.

An oral dose of 0.6 mg per 5 mL of colchicine could aid individuals who have trouble with swallowing pills.

The meaningful results were reported in the DESTINY-Breast09 trial.

Although most health care professionals agree that patients do not need prescriptions for chronic diseases during end-of-life care, patients often receive them anyway.

In contrast to the study findings, the prescribing information for cefiderocol lists different common adverse effects.

Traditional risk factors were more contributable to cryptogenic ischemic stroke (CIS) without patent foramen ovale (PFO), whereas nontraditional ones were more critical for CIS with PFO.

Cases have been confirmed in Mexico and Canada.